贝达喹啉、氯法齐明和利奈唑胺耐药的突变频率及相关基因变异的整理数据。 （你提供的原文似乎不完整，“in”后面缺少具体内容）
Collated data of mutation frequencies and associated genetic variants of bedaquiline, clofazimine and linezolid resistance in .
作者信息
Ismail N, Omar S V, Ismail N A, Peters R P H
机构信息
Department of Medical Microbiology, Faculty of Health Sciences, University of Pretoria, 0002 Prinshof, Gauteng, South Africa.
Centre for Tuberculosis, National Institute for Communicable Diseases, National Health Laboratory Service, Sandringham, Gauteng, South Africa.
出版信息
Data Brief. 2018 Sep 24;20:1975-1983. doi: 10.1016/j.dib.2018.09.057. eCollection 2018 Oct.
Abstract
A comprehensive literature search was conducted to obtain previously published resistance associated mutations for bedaquiline, clofazimine and linezolid for . Where possible, mutation frequencies for these three drugs were also identified. This catalog of previously published mutations could serve as a reference for comparing mutations associated with either in vitro or clinical resistant mutants. The usage of these data was seen in our study relating to approaches for resistance mutant creation (in vitro approaches for generation of mutants resistant to bedaquiline, clofazimine or linezolid and identification of associated genetic variants (Ismail et al., 2018 in press). Previously published mutations for clofazimine were described in the and genes, for bedaquiline in , and () genes and for linezolid in the and genes.
摘要
进行了全面的文献检索，以获取先前发表的针对贝达喹啉、氯法齐明和利奈唑胺的耐药相关突变。在可能的情况下，还确定了这三种药物的突变频率。这份先前发表的突变目录可作为比较与体外或临床耐药突变体相关的突变的参考。这些数据的用途在我们关于耐药突变体产生方法的研究中可见（用于产生对贝达喹啉、氯法齐明或利奈唑胺耐药的突变体的体外方法以及相关基因变异的鉴定（伊斯梅尔等人，2018年即将发表））。先前发表的氯法齐明突变见于 和 基因，贝达喹啉突变见于 、 和 （）基因，利奈唑胺突变见于 和 基因。
相似文献
1
Collated data of mutation frequencies and associated genetic variants of bedaquiline, clofazimine and linezolid resistance in .贝达喹啉、氯法齐明和利奈唑胺耐药的突变频率及相关基因变异的整理数据。 （你提供的原文似乎不完整，“in”后面缺少具体内容）
Data Brief. 2018 Sep 24;20:1975-1983. doi: 10.1016/j.dib.2018.09.057. eCollection 2018 Oct.
2
In vitro approaches for generation of Mycobacterium tuberculosis mutants resistant to bedaquiline, clofazimine or linezolid and identification of associated genetic variants.用于产生对贝达喹啉、氯法齐明或利奈唑胺耐药的结核分枝杆菌突变体及鉴定相关基因变异的体外方法。
J Microbiol Methods. 2018 Oct;153:1-9. doi: 10.1016/j.mimet.2018.08.011. Epub 2018 Aug 28.
3
Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in southern Africa: a phenotypic and phylogenetic analysis.南部非洲耐多药结核病患者中贝达喹啉和氯法齐明耐药相关变异体的人群水平出现：表型和系统发育分析。
Lancet Microbe. 2020 Aug;1(4):e165-e174. doi: 10.1016/S2666-5247(20)30031-8.
4
Genetic variants and their association with phenotypic resistance to bedaquiline in : a systematic review and individual isolate data analysis.遗传变异及其与贝达喹啉对表型耐药性的关联：系统评价和个体分离株数据分析。
Lancet Microbe. 2021 Nov;2(11):e604-e616. doi: 10.1016/s2666-5247(21)00175-0. Epub 2021 Aug 31.
5
Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid.新型和重新定位的抗结核分枝杆菌药物贝达喹啉、氯法齐明、利奈唑胺、德拉马尼和普托马尼耐药相关突变的系统评价。
J Antimicrob Chemother. 2020 Aug 1;75(8):2031-2043. doi: 10.1093/jac/dkaa136.
6
Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis.pepQ基因突变赋予结核分枝杆菌对贝达喹啉和氯法齐明的低水平耐药性。
Antimicrob Agents Chemother. 2016 Jul 22;60(8):4590-9. doi: 10.1128/AAC.00753-16. Print 2016 Aug.
7
Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region.对来自莫斯科地区的耐贝达喹啉和利奈唑胺的结核分枝杆菌分离株的检测。
J Antimicrob Chemother. 2017 Jul 1;72(7):1901-1906. doi: 10.1093/jac/dkx094.
8
Bedaquiline- and clofazimine- selected Mycobacterium tuberculosis mutants: further insights on resistance driven largely by Rv0678.贝达喹啉和氯法齐明选择的结核分枝杆菌突变体：对主要由 Rv0678 驱动的耐药性的进一步了解。
Sci Rep. 2023 Jun 27;13(1):10444. doi: 10.1038/s41598-023-36955-y.
9
Mutations in Rv0678, Rv2535c, and Rv1979c Confer Resistance to Bedaquiline in Clinical Isolates of Mycobacterium Tuberculosis.结核分枝杆菌临床分离株中 Rv0678、Rv2535c 和 Rv1979c 基因突变可导致对贝达喹啉的耐药性。
Curr Mol Pharmacol. 2024;17:e18761429314641. doi: 10.2174/0118761429314641240815080447.
10
Emergence of Canonical and Noncanonical Genomic Variants following Exposure of Clinical Mycobacterium tuberculosis Strains to Bedaquiline or Clofazimine.临床结核分枝杆菌菌株暴露于贝达喹啉或氯法齐明后，典型和非典型基因组变异的出现。
Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0136822. doi: 10.1128/aac.01368-22. Epub 2023 Mar 9.
引用本文的文献
1
Linking genetic and phenotypic bedaquiline resistance in Mycobacterium tuberculosis strains from Georgia.关联格鲁吉亚结核分枝杆菌菌株中贝达喹啉耐药性的基因与表型
PLoS One. 2025 Jul 15;20(7):e0326794. doi: 10.1371/journal.pone.0326794. eCollection 2025.
2
Chemical genetic interactions elucidate pathways controlling tuberculosis antibiotic efficacy during infection.化学遗传相互作用阐明了感染期间控制结核病抗生素疗效的途径。
Proc Natl Acad Sci U S A. 2025 Mar 4;122(9):e2417525122. doi: 10.1073/pnas.2417525122. Epub 2025 Feb 24.
3
Mice infected with . with mutations still benefit from bedaquiline treatment.感染了……且有……突变的小鼠仍能从贝达喹啉治疗中获益。 （原文中“with...”部分表述不完整）
IJTLD Open. 2024 Nov 1;1(11):525-527. doi: 10.5588/ijtldopen.23.0527. eCollection 2024 Nov.
4
Impact of primary percutaneous coronary intervention on ST-segment elevation myocardial infarction patients: A comprehensive analysis.直接经皮冠状动脉介入治疗对ST段抬高型心肌梗死患者的影响：一项综合分析。
World J Exp Med. 2024 Mar 20;14(1):88541. doi: 10.5493/wjem.v14.i1.88541.
5
Multidrug-resistant tuberculosis.耐多药结核病。
Nat Rev Dis Primers. 2024 Mar 24;10(1):22. doi: 10.1038/s41572-024-00504-2.
6
Detection of a historic reservoir of bedaquiline/clofazimine resistance-associated variants in Mycobacterium tuberculosis.检测结核分枝杆菌中与贝达喹啉/氯法齐明耐药相关变异的历史储存库。
Genome Med. 2024 Feb 19;16(1):34. doi: 10.1186/s13073-024-01289-5.
7
Bedaquiline, Delamanid, Linezolid, Clofazimine, and Capreomycin MIC Distributions for Drug Resistance in Shanghai, China.中国上海贝达喹啉、地拉曼尼、利奈唑胺、氯法齐明和卷曲霉素对耐药性的最低抑菌浓度分布
Infect Drug Resist. 2023 Dec 11;16:7587-7595. doi: 10.2147/IDR.S440711. eCollection 2023.
8
Bedquiline Resistance Mutations: Correlations with Drug Exposures and Impact on the Proteome in M. tuberculosis.耐药突变相关的药物暴露和对结核分枝杆菌蛋白质组的影响
Antimicrob Agents Chemother. 2023 Jul 18;67(7):e0153222. doi: 10.1128/aac.01532-22. Epub 2023 May 31.
9
Emergence of Canonical and Noncanonical Genomic Variants following Exposure of Clinical Mycobacterium tuberculosis Strains to Bedaquiline or Clofazimine.临床结核分枝杆菌菌株暴露于贝达喹啉或氯法齐明后，典型和非典型基因组变异的出现。
Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0136822. doi: 10.1128/aac.01368-22. Epub 2023 Mar 9.
10
Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement.结核分枝杆菌分子药物耐药检测的临床意义：2023 年 TBnet/RESIST-TB 共识声明。
Lancet Infect Dis. 2023 Apr;23(4):e122-e137. doi: 10.1016/S1473-3099(22)00875-1. Epub 2023 Feb 28.
本文引用的文献
1
In vitro approaches for generation of Mycobacterium tuberculosis mutants resistant to bedaquiline, clofazimine or linezolid and identification of associated genetic variants.用于产生对贝达喹啉、氯法齐明或利奈唑胺耐药的结核分枝杆菌突变体及鉴定相关基因变异的体外方法。
J Microbiol Methods. 2018 Oct;153:1-9. doi: 10.1016/j.mimet.2018.08.011. Epub 2018 Aug 28.
2
Mutations associated with in vitro resistance to bedaquiline in Mycobacterium tuberculosis isolates in Australia.澳大利亚结核分枝杆菌分离株中与体外对贝达喹啉耐药相关的突变
Tuberculosis (Edinb). 2018 Jul;111:31-34. doi: 10.1016/j.tube.2018.04.007. Epub 2018 Apr 25.
3
Defining Bedaquiline Susceptibility, Resistance, Cross-Resistance and Associated Genetic Determinants: A Retrospective Cohort Study.定义贝达喹啉敏感性、耐药性、交叉耐药性及其相关遗传决定因素：一项回顾性队列研究。
EBioMedicine. 2018 Feb;28:136-142. doi: 10.1016/j.ebiom.2018.01.005. Epub 2018 Jan 9.
4
Isolation and Characterization of Oxazolidinone-Resistant Mycobacterium tuberculosis.异恶唑烷酮类耐药结核分枝杆菌的分离与鉴定。
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.01296-17. Print 2017 Oct.
5
Drug Susceptibility of Bedaquiline, Delamanid, Linezolid, Clofazimine, Moxifloxacin, and Gatifloxacin against Extensively Drug-Resistant Tuberculosis in Beijing, China.贝达喹啉、德拉马尼、利奈唑胺、氯法齐明、莫西沙星和加替沙星对中国北京广泛耐药结核病的药敏性。
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.00900-17. Print 2017 Oct.
6
Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region.对来自莫斯科地区的耐贝达喹啉和利奈唑胺的结核分枝杆菌分离株的检测。
J Antimicrob Chemother. 2017 Jul 1;72(7):1901-1906. doi: 10.1093/jac/dkx094.
7
Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis.耐多药结核病患者分离株中对氯法齐明和贝达喹啉的原发性耐药情况。
Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.00239-17. Print 2017 Jun.
8
Rapid emergence of bedaquiline resistance: lessons to avoid repeating past errors.贝达喹啉耐药性的迅速出现：避免重蹈覆辙的教训。
Eur Respir J. 2017 Mar 22;49(3). doi: 10.1183/13993003.01719-2016. Print 2017 Mar.
9
Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline.在未记录有先前使用氯法齐明或贝达喹啉情况的耐多药结核病患者中，与耐药相关的Rv0678变体意外地具有高流行率。
J Antimicrob Chemother. 2017 Mar 1;72(3):684-690. doi: 10.1093/jac/dkw502.
10
Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis.pepQ基因突变赋予结核分枝杆菌对贝达喹啉和氯法齐明的低水平耐药性。
Antimicrob Agents Chemother. 2016 Jul 22;60(8):4590-9. doi: 10.1128/AAC.00753-16. Print 2016 Aug.
Zotero 插件